Effects of Renin-Angiotensin-Aldosterone System Blockade in Patients with End-Stage Renal Disease

Teresa Slomka, Emily S. Lennon, Hina Akbar, Elvira O. Gosmanova, Syamal Bhattacharya, Carrie S. Oliphant, Rami Khouzam

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

Blockers of the renin-angiotensin-aldosterone system (RAAS), such as angiotensin-converting enzyme inhibitors and angiotensin receptor blockers are routinely used in patients with chronic kidney disease because of their cardiovascular (CV) and renoprotective effects. However, there are no uniform recommendations about RAAS blockers for CV protection in the end-stage renal disease (ESRD) population other than the preferred drug class for blood pressure control. This uncertainty stems from the fact that patients with ESRD were generally excluded from randomized controlled trials evaluating the cardioprotective benefits of RAAS blockers. It is important to weigh the potential harms associated with the use of RAAS blockers, such as electrolyte disturbances and worsening anemia, with their role in protection of residual kidney function, alleviation of thirst and potential CV benefits. The objective of this review is to summarize the current knowledge about the use of RAAS blockers in patients with ESRD.

Original languageEnglish (US)
Pages (from-to)309-316
Number of pages8
JournalAmerican Journal of the Medical Sciences
Volume351
Issue number3
DOIs
StatePublished - Jan 1 2016

Fingerprint

Renin-Angiotensin System
Chronic Kidney Failure
Thirst
Angiotensin Receptor Antagonists
Chronic Renal Insufficiency
Angiotensin-Converting Enzyme Inhibitors
Electrolytes
Uncertainty
Anemia
Randomized Controlled Trials
Blood Pressure
Kidney
Pharmaceutical Preparations
Population

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Effects of Renin-Angiotensin-Aldosterone System Blockade in Patients with End-Stage Renal Disease. / Slomka, Teresa; Lennon, Emily S.; Akbar, Hina; Gosmanova, Elvira O.; Bhattacharya, Syamal; Oliphant, Carrie S.; Khouzam, Rami.

In: American Journal of the Medical Sciences, Vol. 351, No. 3, 01.01.2016, p. 309-316.

Research output: Contribution to journalReview article

Slomka, Teresa ; Lennon, Emily S. ; Akbar, Hina ; Gosmanova, Elvira O. ; Bhattacharya, Syamal ; Oliphant, Carrie S. ; Khouzam, Rami. / Effects of Renin-Angiotensin-Aldosterone System Blockade in Patients with End-Stage Renal Disease. In: American Journal of the Medical Sciences. 2016 ; Vol. 351, No. 3. pp. 309-316.
@article{b3f98680df974a37b78fb5b83e647b82,
title = "Effects of Renin-Angiotensin-Aldosterone System Blockade in Patients with End-Stage Renal Disease",
abstract = "Blockers of the renin-angiotensin-aldosterone system (RAAS), such as angiotensin-converting enzyme inhibitors and angiotensin receptor blockers are routinely used in patients with chronic kidney disease because of their cardiovascular (CV) and renoprotective effects. However, there are no uniform recommendations about RAAS blockers for CV protection in the end-stage renal disease (ESRD) population other than the preferred drug class for blood pressure control. This uncertainty stems from the fact that patients with ESRD were generally excluded from randomized controlled trials evaluating the cardioprotective benefits of RAAS blockers. It is important to weigh the potential harms associated with the use of RAAS blockers, such as electrolyte disturbances and worsening anemia, with their role in protection of residual kidney function, alleviation of thirst and potential CV benefits. The objective of this review is to summarize the current knowledge about the use of RAAS blockers in patients with ESRD.",
author = "Teresa Slomka and Lennon, {Emily S.} and Hina Akbar and Gosmanova, {Elvira O.} and Syamal Bhattacharya and Oliphant, {Carrie S.} and Rami Khouzam",
year = "2016",
month = "1",
day = "1",
doi = "10.1016/j.amjms.2015.12.021",
language = "English (US)",
volume = "351",
pages = "309--316",
journal = "American Journal of the Medical Sciences",
issn = "0002-9629",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Effects of Renin-Angiotensin-Aldosterone System Blockade in Patients with End-Stage Renal Disease

AU - Slomka, Teresa

AU - Lennon, Emily S.

AU - Akbar, Hina

AU - Gosmanova, Elvira O.

AU - Bhattacharya, Syamal

AU - Oliphant, Carrie S.

AU - Khouzam, Rami

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Blockers of the renin-angiotensin-aldosterone system (RAAS), such as angiotensin-converting enzyme inhibitors and angiotensin receptor blockers are routinely used in patients with chronic kidney disease because of their cardiovascular (CV) and renoprotective effects. However, there are no uniform recommendations about RAAS blockers for CV protection in the end-stage renal disease (ESRD) population other than the preferred drug class for blood pressure control. This uncertainty stems from the fact that patients with ESRD were generally excluded from randomized controlled trials evaluating the cardioprotective benefits of RAAS blockers. It is important to weigh the potential harms associated with the use of RAAS blockers, such as electrolyte disturbances and worsening anemia, with their role in protection of residual kidney function, alleviation of thirst and potential CV benefits. The objective of this review is to summarize the current knowledge about the use of RAAS blockers in patients with ESRD.

AB - Blockers of the renin-angiotensin-aldosterone system (RAAS), such as angiotensin-converting enzyme inhibitors and angiotensin receptor blockers are routinely used in patients with chronic kidney disease because of their cardiovascular (CV) and renoprotective effects. However, there are no uniform recommendations about RAAS blockers for CV protection in the end-stage renal disease (ESRD) population other than the preferred drug class for blood pressure control. This uncertainty stems from the fact that patients with ESRD were generally excluded from randomized controlled trials evaluating the cardioprotective benefits of RAAS blockers. It is important to weigh the potential harms associated with the use of RAAS blockers, such as electrolyte disturbances and worsening anemia, with their role in protection of residual kidney function, alleviation of thirst and potential CV benefits. The objective of this review is to summarize the current knowledge about the use of RAAS blockers in patients with ESRD.

UR - http://www.scopus.com/inward/record.url?scp=84963595178&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84963595178&partnerID=8YFLogxK

U2 - 10.1016/j.amjms.2015.12.021

DO - 10.1016/j.amjms.2015.12.021

M3 - Review article

VL - 351

SP - 309

EP - 316

JO - American Journal of the Medical Sciences

JF - American Journal of the Medical Sciences

SN - 0002-9629

IS - 3

ER -